Theranostics 2019, 9, 8061-8072.
时间:2020-01-09

Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Melanoma


There is tremendous interest in integratingCTimaging withchemotherapy; however, reported iodine-based nanosystems such as nanogels and nano-emulsions display typically reduced contrast coefficient, lowdrug loading and stability, and poor targetability. Here, cRGD-functionalizeddisulfide-crosslinkediodine-richpolymersomes (cRGD-XIPs) were designed as a novel,robust andsmarttheranosticagent and investigated fortargetedCTimaging andchemotherapy of malignant tumors.Methods:cRGD-XIPs were prepared from co-self-assembly of poly(ethylene glycol)-b-poly(dithiolane trimethylene carbonate-co-iodinated trimethylene carbonate) (PEG-P(DTC-IC)) and cRGD-PEG-P(DTC-IC) block copolymers.In vitroandin vivoCT contrast effect of cRGD-XIPs was studied using αvβ3-overexpressing B16melanoma as a tumor model in comparison with clinicalagent iohexol. The therapeutic efficacy of doxorubicin-loaded cRGD-XIPs (cRGD-XIPs-Dox) to B16melanoma was investigated and compared with XIPs-Dox (non-targeted), cRGD-IPs-Dox (non-crosslinked) and free Dox.Results:cRGD-XIPs were formed with 55.5 wt.% iodine and ca. 90 nm in diameter. cRGD-XIPs-Dox with a Dox loading of 15.3wt.% bared superior colloidal stability and reduction-responsivedrug release. Notably, blank cRGD-XIPs showed a maximum-tolerated dose (MTD) > 400 mg iodine equiv./kg while cRGD-XIPs-Dox had an MTD > 150 mg Dox equiv./kg, ca. 15-fold improvement over free Dox. cRGD-XIPs revealed superiorCT contrast effect and achieved 46.5- and 24.0-fold better enhancement ofCTimaging of B16melanoma than iohexol at 4 h following intratumoral and intravenous injection, respectively. cRGD-XIPs-Dox displayed an elimination half-life of 6.5 h and an elevated accumulation of 6.68% ID/g in the tumors. Furthermore, cRGD-XIPs-Dox was significantly more effective than XIPs-Dox and cRGD-XPs-Dox in inhibiting growth of B16melanomamodel.Conclusion:This proof-of-concept study demonstrates that cRGD-XIPs are arobust, non-toxic andsmart polymerictheranosticagent that can not only significantly enhanceCTimaging of tumors but also mediate efficient tumor-targetedchemotherapy. XIPs offer a unique and safe platform fortheranosticpolymersomes that pre-select patients usingCTimaging prior totargetedchemotherapy with the same system.


Y. Zou, Y.H. Wei, J. Bao, F.R. Yao, Z.K. Li, Y.P. Sun, F.H. Meng*, C.H. Hu, G. Storm, and Z.Y. Zhong*, Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Melanoma,Theranostics2019, 9, 8061-8072.